Business
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
Enrollment completed in ML-007C-MA’s ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004’s IRIS Phase 2 trial in autism spectrum disorderTopline results from both Phase 2 trials expected by mid-August 2026 SAN FRANCISCO and BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced c
About this update from Maplight Therapeutics, Inc.
[{"type":"image","alt":"MapLight Therapeutics, Inc.","displaySize":"","headline":null,"caption":"MapLight Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/941d8d85f6b637b4194ef76437eebab4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fODzuGMXWGqW2tk5Npmksw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2/https://media.zenfs.com/en/globenewswire.com/941d8d85f6b637b4194ef76437eebab4","width":300,"height":54}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment completed in ML-007C-MA’s ZEPHYR Phase 2 trial in schizophrenia ","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"Last patient visit completed for ML-004’s IRIS Phase 2 trial in autism spectrum disorder","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline results from both Phase 2 trials expected by mid-August 2026","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":230,"olType":false},{"type":"text","content":"SAN FRANCISCO and BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced completion of enrollment in its Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia. The Company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluating ML-004 for the treatment of autism spectrum disorder. The Company expects to report topline results from both Phase 2 trials by mid-August 2026.","length":624,"tagName":"p"},{"type":"text","content":""The robust enrollment in the ZEPHYR trial reflects the critical unmet need for new treatment options in schizophrenia," said Chris Kroeger, Co-Founder and Chief Executive Officer. "We are grateful for the enthusiasm and commitment of both participants and investigators that enabled efficient study conduct while maintaining high quality standards. 2026 is shaping up to be an important year for MapLight and we look forward to sharing the topline data from these trials."","length":493,"tagName":"p"},{"type":"text","content":"The Phase 2 ZEPHYR trial is a randomized, double-blind, placebo-controlled trial evaluating th...